Cue Biopharma is trading at $18.54, down 5.72%, during the November 5 session; no fresh company-specific announcement explaining the decline surfaced. - The latest identified company news was positive CUE-221 Phase 2 results in September. - Reuters reported chip and data-center-related stocks under pressure after the midterm results on November 5, amid broader risk-off trading. - Supplied context shows biotech rising, so the move does not appear to reflect a sector-wide biotech selloff.